The revised Swiss Therapeutic Products Act (TPA) and its related ordinances entered into force on 1 January 2019. The modifications aim at creating new and simpler access opportunities for certain medicinal product categories, improving drug safety and enhancing transparency by increasing the scope of the information published by Swissmedic.

This webinar will address important changes and implications for industry

• Art. 13
• Simplified authorisation procedure
• Temporary marketing authorisation
• Paediatric Investigation Plan
• Orphan drugs and data protection
• Increase of transparency
• SwissPAR

For more information and registration click here.